Abstract: The present application provides a method, apparatus, device and medium for virtual interaction, wherein the method includes: presenting a media content stream in a virtual space, wherein the media content stream includes at least one interactive object; switching a current camera position to a target camera position according to interactive indication information; presenting an interactive trigger zone and the interactive object in interactive space of the target camera position; and interacting with the interactive object according to the interactive trigger zone. The present application makes interactive operations of the user in the virtual space more vivid and rich, and thus enhances interactivity of the user in the virtual space and improves interactive quality of the virtual interaction.

Abstract: Provided are an antibody against claudin 18.2 (CLDN18.2) and a use thereof in diagnosing and treating cancer of the stomach, pancreas and esophagus.

Abstract: A terminal roaming method, an apparatus, and a wireless local area network are disclosed, and belong to the field of WLAN technologies. A session parameter used when a terminal performs data exchange with an original associated AP is migrated to a roaming target AP. After the terminal is associated with the roaming target AP, the roaming target AP can continue data exchange with the terminal based on the migrated session parameter, and the terminal can also continue data exchange with the roaming target AP based on the session parameter used when the terminal performs data exchange with the original associated AP. The terminal and the roaming target AP do not need to perform session negotiation again, to shorten a data service recovery time required after a roaming handover of the terminal, and reduce a service transmission delay. This improves smoothness of roaming handover of the terminal.

Abstract: The present invention relates to a claudin 18.2 (CLDN18.2) antibody and the use thereof in treating cancers, such as gastric cancer, pancreatic cancer, and esophageal cancer.

Abstract: The present application relates to an anti-CD47 single-domain antibody and a use thereof, and a method for preparing the antibody. The single-domain antibody comprises a CDR selected from the following CDRs: (1) CDR1, CDR2, and CDR3 shown by SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO:3; or (2) CDR1, CDR2, and CDR3 shown by SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8.

Abstract: Disclosed is a 2-morpholin-4,6-disubstituted pyrimidine derivative as shown in formula (1) below, and a pharmaceutically acceptable salt, solvate, stereoisomer or prodrug thereof, and a pharmaceutical composition thereof and a use thereof, wherein the definition of each group is as shown in the description. The compound has a PI3K kinase inhibition activity, and has a relatively high inhibitive ability and a low cytotoxicity against PIK3CA mutant breast cancer cell strains T47D and MCF-7.

Abstract: Azabicyclo derivatives, a preparation process, and medical use thereof are provided. In particular, azabicyclo derivatives of formula (I), pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs thereof are described. The azabicyclo derivatives of formula (I) are useful as Epidermal Growth Factor Receptor (EGFR) inhibitors. The definitions of the variable R groups in the azabicyclo derivatives of formula (I) are described in the specification.

Abstract: The present invention relates to a 2,4-disubstituted 7H-pyrrolo[2,3-d]pyrimidine derivative, a preparation method and a medicinal use thereof. In particular, the present invention discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof. For the definition of each group in formula (I), see the description tbr details.

Abstract: The present invention relates to 2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, a preparation method therefor and a medicinal use thereof. Specifically, disclosed are compounds of formula (I) or pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs, preparation method therefor and application thereof. Definition of each group in the formula can be found in the specification for details.

Abstract: Disclosed is a 2-morpholin-4,6-disubstituted pyrimidine derivative as shown in formula (1) below, and a pharmaceutically acceptable salt, solvate, stereoisomer or prodrug thereof, and a pharmaceutical composition thereof and a use thereof, wherein the definition of each group is as shown in the description. The compound has a PI3K kinase inhibition activity, and has a relatively high inhibitive ability and a low cytotoxicity against PIK3CA mutant breast cancer cell strains T47D and MCF-7.

Abstract: Azabicyclo derivatives, a preparation process, and medical use thereof are provided. In particular, azabicyclo derivatives of formula (I), pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs thereof are described. The azabicyclo derivatives of formula (I) are useful as Epidermal Growth Factor Receptor (EGFR) inhibitors. The definitions of the variable R groups in the azabicyclo derviatives of formula (I) are described in the specification.

Abstract: The present invention relates to a 2,4-disubstituted 7H-pyrrolo[4,3-d]pyrimidin derivative, a preparation method and a medicinal use thereof. In particular, the present invention discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof. For the definition of each group in formula (I), see the description tbr details.

Abstract: The present invention relates to 2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, a preparation method therefor and a medicinal use thereof. Specifically, disclosed are compounds of formula (I) or pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs, preparation method therefor and application thereof. Definition of each group in the formula can be found in the specification for details.